Last reviewed · How we verify
Leveraging Social Networks to Increase COVID-19 Testing Uptake
NA trial testing Chain-referral in Covid-19 in 498 participants. Completed in 1 January 2023.
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 498 |
| Start date | 20 April 2021 |
| Primary completion | 18 March 2022 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across United States |
New York State Psychiatric Institute
Adults 18 to 80, any sex, with Covid-19 or Substance Use. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of participants who agreed to take a COVID-19 rapid test out of those who were enrolled (n=498)
| Group | Value | 95% CI |
|---|---|---|
| Chain Referral | 261 | |
| Credible Messenger | 214 |
Mean number of COVID-19 rapid tests taken among those who took at least 1 test (n=478)
| Group | Value | 95% CI |
|---|---|---|
| Chain Referral | 1.8 | ± 1.75 |
| Credible Messenger | 1.6 | ± 1.35 |
Total number of coupons redeemed (Chain referral arm) out of coupons delivered OR total number of people approached in the community via credible messengers (Credible messenger arm) who enrolled in the study
| Group | Value | 95% CI |
|---|---|---|
| Chain Referral | 271 | |
| Credible Messenger | 227 |
Number of people reached or approached via coupon (CR) based on number of coupons distributed or via peer/direct contact (CM), who may or may not have enrolled in the study
| Group | Value | 95% CI |
|---|---|---|
| Chain Referral | 624 | |
| Credible Messenger | 468 |
Time frame: Baseline assessment period, up to 2 weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
| Reaction | System | Chain Referral | Credible Messenger |
|---|---|---|---|
| suicidal ideation | Psychiatric disorders | — | — |
Data from ClinicalTrials.gov NCT04873401 adverse events section.
This two-year project will adapt and conduct a trial examining the ability of two recruitment strategies, chain-referral and credible messenger, to reach those who use opioids and other substances in order to increase their uptake of onsite point of care COVID-19 testing that will be delivered in two community based organizations (CBOs): Alliance for Positive Change and Argus Health Inc. In Phase 1, Adapt two implementation strategies to support COVID-19 testing uptake and sustainability, adapting elements of existing efficacious social network-based interventions via a CBPR approach. In Phase 2, we will examine and compare the efficacy of two sets of implementation strategies on (i) reach, (ii) testing uptake, (iii) service delivery (i.e. quarantine, medical care, contact tracing) and (iv) sustainability for individuals who use opioids and other drugs. In Phase 3, Elucidate and compare the system/organizational-, staff-, and individual-level factors that influence implementation (i.e. fidelity, acceptability, feasibility, sustainability) of the strategies to develop a plan for dissemination and scale-up in other CBOs who serve opioid and other substance using individuals in NYC.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04873401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing